Mode
Text Size
Log in / Sign up
Phase 3 Completed N=341 Randomized Single-blind Treatment

Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu

Upper Respiratory Tract Infection · Nasal Congestion · Rhinorrhea · Sneezing
Source: ClinicalTrials.gov NCT01448057 ↗
Enrolled (actual)
341
Serious AEs
0.0%
Results posted
Jan 2017
Primary outcomePrimary: Physician Global Evaluation of Effectiveness on Nasal Symptoms — 1.9; 2.1 score on a scale
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

The study is a clinical evaluation of an over the counter (OTC) combination product containing paracetamol (500 mg), dimethindene maleate (1 mg), phenylephrine hydrochloride (10 mg) compared to paracetamol (500 mg) alone in the treatment of nasal congestion, rhinorrhea, sneezing and other symptoms due to upper respiratory tract infection (URTI).

Outcome Measures

OutcomeResultp-value
PRIMARY
Physician Global Evaluation of Effectiveness on Nasal Symptoms
1.9; 2.1
SECONDARY
Daily Average of the Sum of a 100 mm Visual Analog Scale for All Symptoms
169.2; 225.3

Eligibility Criteria

  • Inclusion criteria:
  • acute URTI, diagnosed by a health care professional at the study site, with the following symptoms having started within 72 hours before the screening/baseline Visit: nasal congestion, sneezing, and rhinorrhea.
  • Exclusion criteria:
  • Use of other investigational drugs within 30 days or 10 half-lives before enrollment, whichever is longer.
  • History of or known hypersensitivity to any of the study drugs, excipients or to drugs of similar chemical classes.

Other protocol-defined inclusion/exclusion criteria may apply

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01448057). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search